ibuprofen in COVID19

Early use of ibuprofen in COVID-19 might a promising agent to attenuate the severity of the disease: A randomized controlled trial

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR202202880140319

Enrollment

100

Registered

2022-02-09

Start date

2022-01-15

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID 19 Respiratory

Interventions

CONTROL GROUP

IBUPROFEN GROUP

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1- Age: 18 - 60 years-old both sex 2. moderate case covid 19 diseases

Exclusion criteria

Exclusion criteria: 1- Severe case covid disease. 2. Advanced liver disease. 3- Renal dysfunction. 4- History of peptic ulcer. 5. History of allergy to ibuprofen or paracetamol. 6. Vaccinated patient by any type of vaccine either single or twice dose

Design outcomes

Primary

Measure	Time frame
The number of patient improved and discharge to home	—

Secondary

Measure	Time frame
1- number of patient transfer to ICU 2 number of patient need oxygen supply to maintain oxygen saturation above 92%. 3. The intermediate unit duration of stay	—

Countries

Egypt

Contacts

Public ContactLOBNA SALEH

lecturer Ain shams university

lobnasaleh_80@yahoo.com00201005246397

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 9, 2026